Chad to Test Sleep Products

CHATSWORTH, Calif.–Respiratory equipment manufacturer Chad
Therapeutics has announced it will begin testing its initial
products for the sleep-disorder market within the coming weeks.

According to company President and CEO Earl Yager, the company
is “making progress with the initial products we are developing for
the sleep-disorder market and with our evaluation of alternative
distribution models for these new products. We plan to conduct the
first formal clinical trial on these products in the next few
weeks, and the results of this test should allow us to move forward
with our distribution options.”

Yager made the announcement as part of the company’s quarterly
earnings summary, released last week. For the company’s third
quarter, which ended Dec. 31, Chad reported a 23 percent rise in
revenue, to $6.4 million, from prior-year results. Net earnings for
the quarter increased 21 percent to $505,000.